Financial Data and Key Metrics Changes - For the full year 2025, net revenues were $719.9 million, with a modest decline of 2% year-over-year due to headwinds in legacy products [6][7] - Fourth quarter sales decreased 2% to $183.1 million from $186.5 million in the previous year, with net income reported at $24.4 million, or $0.51 per share, down from $38 million, or $0.74 per share in the prior year [11][14] - Adjusted net income for the fourth quarter was $34.2 million, or $0.73 per share, compared to $47.2 million, or $0.92 per share in the previous year [15] Business Line Data and Key Metrics Changes - BAQSIMI generated $185.4 million in revenue for the full year, up 12% year-over-year, while Primatene MIST sales rose 7% to $108.7 million [6][7] - In the fourth quarter, BAQSIMI sales grew 12% to $46.7 million, while Primatene MIST sales dropped 3% to $27.9 million [11][12] - Glucagon sales declined 45% to $14.1 million due to increased competition, and epinephrine sales decreased 9% to $17.1 million [12] Market Data and Key Metrics Changes - The company expects mid-single-digit unit growth for BAQSIMI in the U.S., offset by a planned reduction in international volume as it exits unprofitable markets [16][29] - The Atrovent market, associated with Ipratropium Bromide, was valued at $112 million last year, with expectations of meaningful market share due to 180 days of exclusivity [32] Company Strategy and Development Direction - The company aims to transition towards a portfolio anchored in high-value proprietary and biosimilar assets, with significant investments in R&D and manufacturing capabilities [5][9] - The expansion of the U.S. manufacturing facility in Rancho Cucamonga is a critical part of the long-term strategy, expected to quadruple production capacity [9][18] - The company plans to ramp up spending on clinical trials and materials for inhalation and proprietary pipeline products, with a focus on oncology, ophthalmology, and immunology [18][25] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of resilient commercial momentum and strategic pipeline progress, with expectations for consolidated revenue growth in the mid-to-high single-digit range for 2026 [20][17] - Gross margins are expected to be lower in 2026 due to pricing pressures on glucagon and epinephrine, alongside increased input costs [17][39] Other Important Information - The company has over $300 million in cash and short-term investments, with plans to utilize a portion for stock buybacks while also exploring business development opportunities [18][40] - The company achieved several major regulatory milestones in 2025, including FDA approvals for iron sucrose, teriparatide, and Ipratropium Bromide HFA [20][8] Q&A Session Summary Question: Development path for AMP-110 and business development priorities - Management has not yet engaged the FDA regarding AMP-110 but is preparing the program [24] - Business development will focus on areas where the company has or plans to have a presence, including endocrinology and oncology [25] Question: BAQSIMI expectations for 2026 and international sales - BAQSIMI is expected to see mid-single-digit growth in the U.S., with international sales declining in the second half of the year [29][30] Question: Gross margins and buyback plans - BAQSIMI growth will help margins, but declines in glucagon and epinephrine will offset this [39] - The company plans to continue buybacks, with $75 million as a potential high end for the year [40] Question: Competition for Primatene MIST and filing cadence - The patent for Primatene MIST has expired, but management does not anticipate significant competition [45] - The company expects to have 2 filings late this year and 2-3 filings next year [47] Question: Updates on Nanjing Anji in-licensed assets - The company is in the preclinical stage for these assets and is optimistic about their potential [50][51]

Sempra (NYSE:SRE) Q4 2025 Earnings call February 26, 2026 12:00 PM ET Company ParticipantsAllen Nye - CEOJeff Martin - Chairman and CEOKaren Sedgwick - EVP and CFOLouise Bick - VP of Investor RelationsShar Pourreza - Managing Director and Head of North American Power, Infrastructure and UtilitiesConference Call ParticipantsAidan Kelly - Equity Research AnalystAnthony Crowdell - Managing Director and Senior Equity Research AnalystCarly Davenport - VP and Equity Research AnalystDavid Arcaro - Executive Direct ...

Alliant Energy Corporation Q4 2025 Earnings Call February 20, 2026 2025 Q4 Earnings Call 2 ALLIANT ENERGY 2025 Highlights 6.3% 10-year earnings CAGR | Financial Results | 2025 | 2024 | | --- | --- | --- | | GAAP net income (in millions) | $810 | $690 | | GAAP earnings per share (EPS) | $3.14 | $2.69 | | Ongoing EPS | $3.22 | $3.04 | Cautionary Statements Forward-looking Statements The information regarding earnings per share guidance, dividend target, earnings per share growth, load growth, capital expendit ...

Core Insights - The European Commission has granted ImmunityBio authorization for its bladder cancer treatment ANKTIVA, allowing the company to expand its commercial presence across four regulatory jurisdictions in under two years since its initial FDA approval [1][2] - ImmunityBio's stock has experienced a significant increase of 123.73% over the past year, currently trading at $7.46, which is 18.6% above its 20-day simple moving average (SMA) and 159.3% above its 200-day SMA [3] - Analysts have a positive outlook on ImmunityBio, with a consensus Buy rating and an average price target of $11.80, reflecting strong earnings expectations and recent upward revisions in revenue estimates [6] Regulatory and Market Expansion - The authorization includes key markets such as the Kingdom of Saudi Arabia, where ANKTIVA has received approval for two indications, indicating its growing acceptance and potential market impact [1] - ImmunityBio is committed to long-term safety and efficacy follow-ups with trial participants, which is essential for maintaining authorization and possibly expanding indications [2] Stock Performance and Analyst Sentiment - The stock's recent performance shows a robust upward trend, supported by solid fundamentals, despite mixed technical indicators suggesting some bearish pressure [3][4] - Upcoming earnings report is anticipated on March 2, 2026, with analysts finalizing forecasts, indicating heightened investor interest [5] - Recent analyst actions include maintaining a Buy rating and adjusting price targets, with D. Boral Capital maintaining a target of $24.00 and HC Wainwright & Co. raising their target to $10.00 [6]

As filed with the Securities and Exchange Commission on February 12, 2026. Registration No. 333- (I.R.S. Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOVENTRIX, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 20-0372415 (Primary Standard Industrial Classification Code Number) If this Form is a post-e ...

Financial Data and Key Metrics Changes - In Q4 2025, research and development expenses decreased to $6.2 million from $7 million in Q4 2024, reflecting the completion of the SHIELD II Phase 3 trial [15] - General and administrative expenses increased to $1.8 million in Q4 2025 from $1 million in Q4 2024, primarily due to non-cash expenses related to performance-based options [16] - The net loss for Q4 2025 was $8.5 million or $0.41 per share, unchanged from the previous year but improved on a per-share basis from $1.13 in Q4 2024 [16] - For the full year 2025, net loss was $34.2 million or $2.09 per share, compared to a net loss of $29 million or $4.91 per share in 2024 [17] - As of December 31, 2025, the company had $12.9 million in cash and equivalents, with additional gross proceeds of $3.7 million generated from warrant exercises post-quarter [18] Business Line Data and Key Metrics Changes - The company successfully completed the SHIELD II Phase 3 trial for D-PLEX100, achieving its primary and key secondary endpoints [5] - The focus remains on advancing the regulatory pathway for D-PLEX100 and commercial partnership discussions in the U.S. [5][7] Market Data and Key Metrics Changes - The company is engaging with potential U.S. commercial partners that have strong hospital-based commercialization experience [11] - Discussions with partners have progressed to advanced stages, reflecting the strong clinical profile of D-PLEX100 [7] Company Strategy and Development Direction - The company is transitioning from a primarily R&D-focused organization to one preparing for commercialization, with a renewed corporate brand to reflect this change [11][12] - The introduction of Kynatrix technology aims to expand capabilities beyond localized delivery, targeting metabolic diseases with a long-acting GLP-1 receptor agonist program [14] Management's Comments on Operating Environment and Future Outlook - Management believes 2026 could be transformative, with the rolling NDA submission expected to begin by the end of Q1 2026 [9] - Positive feedback from the FDA supports the regulatory pathway for D-PLEX100, with expectations for a rolling NDA submission [6][9] Other Important Information - The company appointed Ms. Brooke Story as chairman of the board in December 2025, bringing extensive experience in medical technology [9] Q&A Session Summary Question: Can you share how discussions around the scope of the label progressed? - The company is targeting an initial label for the prevention of surgical site infections in abdominal colorectal surgery, supported by Phase 3 data [22] Question: Any thoughts on plans for broader label expansion? - There may be opportunities for label expansion into broader abdominal surgical applications as the review process progresses [24] Question: What work is being done to prepare for potential approval of D-PLEX100? - The company is focusing on building awareness, market research, and creating a KOL network to prepare for commercialization [32] Question: How do you view the strategic timing for the GLP-1 program? - The company plans to partner at an early stage, leveraging robust preclinical data to attract interest [35] Question: What factors will play a role in identifying the final partner? - The ideal partner will have broad hospital-based capabilities and presence in the surgical suite [41] Question: What percentage of potential target IDNs would likely include D-PLEX on formulary within the first 12 months after approval? - The uptake will take time, with a few months before seeing meaningful updates, but once on formulary, usage is expected to grow steadily [50]

https://t.co/FyOohiuiti wins UK regulatory approval, expanding its footprint as crypto firms race toward legitimacy in major markets.Read more: https://t.co/3qEfJU0YF7 ...

Core Viewpoint - Paramount Skydance Corp. is actively seeking to complete the Justice Department's antitrust review of its tender offer for Warner Bros. Discovery Inc. shares in the coming weeks, as it aims to counter Netflix's planned acquisition of Warner Bros. studios and streaming businesses [1][3]. Group 1: Regulatory Review and Approval - Paramount is providing requested information to the Justice Department, which will require a 10-day waiting period to determine if it will challenge Paramount's proposal due to competition concerns [2]. - The Justice Department is thoroughly examining the offers from both Netflix and Paramount, with federal officials reaching out to major Hollywood constituencies for information [6]. - A Justice Department approval does not guarantee that Paramount is clear of regulatory hurdles, as any changes to key terms of the proposal may require resubmission for review [7]. Group 2: Competitive Landscape - Warner Bros. agreed to sell its studios and streaming divisions to Netflix for $82.7 billion, favoring this deal over Paramount's competing bid [4]. - Paramount has resisted increasing its $108 billion bid for Warner Bros., asserting that its offer is superior and more likely to gain regulatory approval [8]. - Warner Bros. and Netflix express confidence in securing approval for their deal, while also acknowledging that the Justice Department's review is expected to extend into later this year [9]. Group 3: Strategic Implications - Securing early regulatory approval is crucial for Paramount to persuade Warner Bros. shareholders to vote against the Netflix deal [3]. - Paramount's strategy includes appealing directly to shareholders and lobbying regulators to bypass the Netflix deal [4]. - A spokesperson for Netflix indicated that the company expects Paramount to declare compliance with federal regulations, emphasizing the value of the Netflix and Warner Bros. partnership [5].

As filed with the U.S. Securities and Exchange Commission on February 6, 2026 Registration No. 333-292260 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Envoy Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Delaware 3842 86-1369123 (IRS Employer Identification Number) 4875 White Bear Parkw ...

Might those shareholders be more thrilled if you get a sweetened offer from Paramount. Skydance's If they pony up $34, would that that complicate things. If we receive a revised proposal from Paramount, we will do what we have done for months, which is we will consider it on its terms, on the merits, not based on what they say they will do or may do in the media, but what they actually are willing to commit to in a legal document.Value and certainty are our separate but entirely related. It's excellent to s ...